LY 3298176

Drug Profile

LY 3298176

Alternative Names: LY3298176

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 31 Oct 2017 Eli Lilly plans a phase I trial for Type-2 diabetes mellitus (In adults, In the elderly) in Japan in November 2017 (NCT03322631)
  • 19 Oct 2017 Eli Lilly initiates enrolment in a phase II trial for Type-2 diabetes mellitus in USA (SC) (NCT03311724)
  • 17 Oct 2017 Eli Lilly plans a phase II trial for Type-2 diabetes mellitus (SC) (NCT03311724)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top